CONVERGE - Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF)
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.
Also called NCT01984346
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 170 participants
- Sponsor
- Registry
-
NCT01984346
-
- Other papers using this trial's data
- Hybrid Convergent Procedure for the Treatment of Persistent and Long-Standing Persistent Atrial Fibrillation: Results of CONVERGE Clinical Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01984346. Randomized; no masking; primary purpose treatment. Start 2013-12 (registry gives no type); primary completion 2019-08 (actual). Results posted on 2022-02-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CONVERGE - Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF)
- Acronym
- CONVERGE
- Condition
- Persistent Atrial Fibrillation
- Intervention (Device)
- AtriCure EPi-Sense-AF Guided Coagulation System with VisiTrax
- Intervention (Device)
- Endocardial RF Catheter ablation using Open Irrigated-tip RF Abaltion Catheter with unidirectional or bidirectional steering
- Lead sponsor
- AtriCure, Inc.
Record details
- Record id
cardio:ct-nct01984346- Content hash
2d31a6c264d6613550bb478a7ada165802ef2f29e43d6acb6ef9ed9b293ee24c